The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases.

[1]  N. Carr,et al.  M30 expression demonstrates apoptotic cells, correlates with in situ end-labeling, and is associated with Ki-67 expression in large intestinal neoplasms. , 2009, Archives of pathology & laboratory medicine.

[2]  Jilly F. Evans,et al.  Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. , 2003, Cancer research.

[3]  P. Guillou,et al.  Interstitial cell cyclooxygenase‐2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas , 2002, Journal of Pathology.

[4]  R. Yamazaki,et al.  Selective cyclooxygenase‐2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells , 2002, FEBS letters.

[5]  C Michael Stein,et al.  COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease , 2002, The Lancet.

[6]  P. Guillou,et al.  Analysis of Cyclooxygenase Expression in Human Colorectal Adenomas , 2002, Diseases of the colon and rectum.

[7]  C. Cho,et al.  Antiangiogenic effect of a highly selective cyclooxygenase-2 inhibitor on gastric ulcer healing in rats. , 2002, Toxicology and applied pharmacology.

[8]  S. Seki,et al.  Inhibitory effect of a selective cyclooxygenase‐2 inhibitor on liver metastasis of colon cancer , 2002, International journal of cancer.

[9]  A. Harris,et al.  Drug inhibition of angiogenesis. , 2002, Current opinion in pharmacology.

[10]  H. Konno,et al.  The role of cyclooxygenase-2 (COX-2) in two different morphological stages of intestinal polyps in APCΔ474 knockout mice , 2002 .

[11]  G. Triadafilopoulos,et al.  Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. , 2002, Gastroenterology.

[12]  D. McConkey,et al.  Comparative study of various biological parameters, including expression of survivin, between primary and metastatic human colonic adenocarcinomas. , 2002, Anticancer research.

[13]  A. Kato,et al.  COX‐2, prostanoids and colon cancer , 2002 .

[14]  N. Hayashi,et al.  Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. , 2002, Cancer research.

[15]  J. Masferrer,et al.  Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. , 2002, Cancer research.

[16]  A. Raz.  Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer. , 2002, Biochemical pharmacology.

[17]  E. van Marck,et al.  Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia , 2001, The Journal of pathology.

[18]  H. Choy,et al.  A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  Rajnish A. Gupta,et al.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.

[20]  A. Dicker,et al.  Targeting Angiogenic Processes by Combination Rofecoxib and Ionizing Radiation , 2001, American journal of clinical oncology.

[21]  P. Bachellier,et al.  Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? , 2001, American journal of surgery.

[22]  A. Hsu,et al.  Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. , 2001, Advances in enzyme regulation.

[23]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Annals of internal medicine.

[24]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[25]  C. Hawkey,et al.  Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. , 2001, Gastroenterology.

[26]  B. Leggett,et al.  Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status , 2001, Gut.

[27]  G. Peters,et al.  5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  S. Saji,et al.  Therapeutic Effect of TNP-470 on Spontaneous Liver Metastasis of Colon Tumors in the Rabbit , 2000, Surgery Today.

[29]  R Day,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[30]  H. Sheng,et al.  Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. , 2000, Cancer research.

[31]  K. Seibert,et al.  The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. , 2000, Cancer research.

[32]  Jilly F. Evans,et al.  Chemoprevention of intestinal polyposis in the APCΔ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor , 2000, American Journal of Gastroenterology.

[33]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[34]  S. Dey,et al.  Host cyclooxygenase-2 modulates carcinoma growth. , 2000, The Journal of clinical investigation.

[35]  A. van Hecken,et al.  Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans , 2000, European Journal of Clinical Pharmacology.

[36]  A. Hsu,et al.  The Cyclooxygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2* , 2000, The Journal of Biological Chemistry.

[37]  M. Hull,et al.  The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. , 2000, European journal of cancer.

[38]  K. Seibert,et al.  Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.

[39]  E. Fosslien.  Biochemistry of Cyclooxygenase (COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia , 2000, Critical reviews in clinical laboratory sciences.

[40]  T. Tsuruo,et al.  Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522 , 1999, British Journal of Cancer.

[41]  Y. Sasaki,et al.  Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[42]  L. Ellis,et al.  Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. , 1999, Cancer research.

[43]  B. Persson,et al.  Immunocytochemical detection and mapping of a cytokeratin 18 neo‐epitope exposed during early apoptosis , 1999, The Journal of pathology.

[44]  R. DuBois,et al.  Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.

[45]  K. Seibert,et al.  Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. , 1998, Cancer research.

[46]  J. Morrow,et al.  Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. , 1997, The Journal of clinical investigation.

[47]  S. Fox,et al.  Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. , 1996, European journal of cancer.

[48]  Bruno C. Hancock,et al.  Suppression of Intestinal Polyposis in Apc Δ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2) , 1996, Cell.

[49]  S. Leurgans,et al.  Tumor angiogenesis in primary and metastatic colorectal cancers , 1996, Diseases of the colon and rectum.

[50]  D. Hanahan,et al.  Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[51]  S. Tsujitani,et al.  Apoptosis occurs more frequently in metastatic foci than in primary lesions of human colorectal carcinomas: Analysis by terminal‐deoxynucleotidyl‐transferase‐mediated dUTP‐biotin nick end labeling , 1996, International journal of cancer.

[52]  W. Bursch,et al.  Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci of rats. , 1990, Carcinogenesis.

[53]  M. Neeman.  Preclinical MRI Experience in Imaging Angiogenesis , 2004, Cancer and Metastasis Reviews.

[54]  S. Fenwick,et al.  Cyclooxygenase-2 expression in colorectal cancer liver metastases , 2004, Clinical & Experimental Metastasis.

[55]  S. Gately.  The Contributions of Cyclooxygenase-2 to Tumor Angiogenesis , 2004, Cancer and Metastasis Reviews.

[56]  A. Dannenberg,et al.  National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms. , 2002, Neoplasia.

[57]  C. Albanese,et al.  Indomethacin induces differential expression of β-catenin, γ-catenin and T-cell factor target genes in human colorectal cancer cells , 2002 .

[58]  L. Ellis,et al.  Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. , 2001, Neoplasia.

[59]  Kenneth F. Schulz,et al.  The CONSORT Statement , 1996 .

[60]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.